|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Spontaneous Bacterial Peritonitis | |||||
| Liver Cirrhosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Fibrosis | |||||
| Peritonitis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Liver Diseases | |||||
| Pathologic Processes | |||||
| Peritoneal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Probiotics and Placebo | |||||
| Probiotics and Norfloxacin | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Norfloxacin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Nucleic Acid Synthesis Inhibitors | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| All India Institute of Medical Sciences, New Delhi | |||||